Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
25
self-reported 11–50 band
Founded
2014
12 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
1
Post IPO equity · Jan 2025 · US$ 10.2M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
PARADIGM BIOPHARMACEUTICALS LIMITED
ABN94169346963
Legal entities
Show as table · Paradigm Biopharmaceuticals: 1 registry entity
| PARADIGM BIOPHARMACEUTICALS LIMITED | ABN 94169346963 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Paradigm’s (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, the non-opioid PPS has genuine disease-modifying potential.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU500 collins; L2 517 Flinders Lane; Melbourne, Victoria 3000Primary
Grid intelligence Members
Funding
Last round · 8 January 2025US$ 10.2MPost IPO equity
Rounds1
Round typePost IPO equity · secondary transaction
Amount (USD)10,200,000
Stage rank6
Investors named0
Since last round1 yr
Funding
Show as table · 1 funding round
| Rounds | 1 |
|---|---|
| Axis | 2014 to 2026 |
| Post IPO equity · 8 Jan 2025 | US$ 10.2M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Paradigm Biopharmaceuticals?
One Victoria entity on the ABR. PARADIGM BIOPHARMACEUTICALS LIMITED (ABN 94 169 346 963), high confidence.
How many people work at Paradigm Biopharmaceuticals?
The record holds 25 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Paradigm Biopharmaceuticals have offices?
One address on record, Australia only. Primary: 500 collins, L2 517 Flinders Lane, Melbourne, Victoria 3000.
Has Paradigm Biopharmaceuticals raised funding?
One round. Latest 8 January 2025: post IPO equity, US$10,200,000.
Which companies are listed alongside Paradigm Biopharmaceuticals?
9 profiles list Paradigm Biopharmaceuticals as a peer — 83rd percentile in Pharmaceutical Manufacturing. It lists ten peers of its own.